SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering ...

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway Vistagen (Nasdaq: VTGN), a late clinical-stage ...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...

Vistagen (VTGN) announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment ...

Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue. The drug developer ...

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy VistaGen Therapeutics, Inc. (NASDAQ: VTGN) could be a solid addition to your portfolio given ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...